GRI Bio, Inc. Files 8-K

Ticker: GRI · Form: 8-K · Filed: May 23, 2025 · CIK: 1824293

Gri Bio, INC. 8-K Filing Summary
FieldDetail
CompanyGri Bio, INC. (GRI)
Form Type8-K
Filed DateMay 23, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financial-statements

TL;DR

GRI Bio filed an 8-K on 5/23/25. Standard reporting.

AI Summary

GRI Bio, Inc. filed an 8-K on May 23, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI BIO, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain significant new information or material events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for GRI Bio, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 23, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 23, 2025.

What is GRI Bio, Inc.'s state of incorporation?

GRI Bio, Inc. is incorporated in Delaware.

What were GRI Bio, Inc.'s former company names?

GRI Bio, Inc.'s former company names were GRI BIO, Inc. and Vallon Pharmaceuticals, Inc.

What is the address of GRI Bio, Inc.'s principal executive offices?

The address of GRI Bio, Inc.'s principal executive offices is 2223 Avenida de la Playa, #208 La Jolla, CA 92037.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding GRI Bio, Inc. (GRI).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing